{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.4","upperLimit":"84.9","value":"72.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the IRC using Lugano Classification. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for progression or death at 24 months with 95% confidence intervals estimated using Greenwood's formula.","dispersionType":"95% Confidence Interval","groups":[{"description":"Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent","id":"OG000","title":"Zanubrutinib"}],"paramType":"NUMBER","populationDescription":"Efficacy analysis set consisted of all participants with a confirmed diagnosis of MZL who received at least 1 dose of study drug; DOR was summarized for responders only, defined as participants with a best overall response of partial response or above.","reportingStatus":"POSTED","timeFrame":"Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported","title":"DOR Event-Free Rate by IRC Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}